There is a trend to longer time to recurrence of lymphoma cells with combined therapy.
Conversely, patients with nonmucinous tumours (N=19) who underwent 5-FU treatment had a median DFS of 46.5 months; the trend of shorter time to recurrence in these patients approached statistical significance (P=0.053).
There was a trend toward a longer time to recurrence in Rituximab-treated patients (1475 days (427 2530) vs 136 days (80 749), p = 0.09).
These numbers are insufficient to reach statistical significance, but the trend to fewer recurrences in the higher dose groups supports the laboratory end point determination.
While the number of included patients was limited, they found a trend to higher recurrence-free survival probability at 42 months of follow-up after artesunate treatment.
It's not just time to recurrence.
Rate of tumor recurrence was 14.6%, with median time to recurrence of 13.1 months.
Recurrence rate and time interval to recurrence were comparable to those of well-matched historical controls.
Two trials have demonstrated a trend to more locoregional recurrences being detected by alternative follow up methods (Grunfeld et al, 1996; Koinberg et al, 2004).
